The company had posted a consolidated net profit of Rs 618.42 crore in the October-December period of the previous financial year, it said in a BSE filing.
However, consolidated net sales rose 8.75 per cent to Rs 3,843.10 crore during the quarter under review as against Rs 3,533.76 crore a year earlier, it added.
Revenue from the global generics segment also grew 7.81 per cent to Rs 3,169.22 crore in the third quarter of FY15. It was Rs 2,939.58 crore in the same period of previous fiscal.